Welcome to our dedicated page for Clearpoint Neuro SEC filings (Ticker: CLPT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
ClearPoint Neuro, Inc. filings document the company's medical-device and therapy-enabling business, including operating results for its brain and spine navigation platforms, CNS drug-delivery services, and neurocritical-care portfolio after the completed IRRAS Holdings acquisition. Form 8-K reports furnish quarterly and annual results, Regulation FD investor presentations, acquisition-related financial statements, pro forma combined financial information, and material-event disclosures.
Proxy materials cover governance matters, director voting, executive compensation, pay-versus-performance data, and equity-award disclosures. The filing record also includes material agreements, capital-structure disclosure, shareholder voting matters, and clinical or regulatory disclosures tied to the company's regulated neurosurgical products and partnered biologics programs.
Richards Timothy T. reported acquisition or exercise transactions in this Form 4 filing.
ClearPoint Neuro director Timothy T. Richards received 442 shares of Common Stock as compensation, valued at $9.10 per share. The award was issued under the company’s Sixth Amended and Restated 2013 Incentive Compensation Plan in payment of fees owed under the Non-Employee Director Compensation Plan.
Following this grant, Richards directly holds 80,196 shares of ClearPoint Neuro common stock. The shares were issued at the closing price of the company’s common stock on March 31, 2026, making this a routine, stock-settled director fee payment rather than an open-market purchase.
The Vanguard Group filed Amendment No. 3 on a Schedule 13G/A reporting zero beneficial ownership of ClearPoint Neuro Inc common stock as of 03/13/2026. The filing explains an internal realignment effective 01/12/2026 that caused certain Vanguard subsidiaries to report holdings separately on a "disaggregated basis" in reliance on SEC Release No. 34-39538.
The amendment lists Amount beneficially owned: 0 and Percent of class: 0%, and states Vanguard and its managed accounts have rights to dividends or proceeds where applicable; no other person holds more than 5% according to the filing.
ClearPoint Neuro, Inc. CEO and President Joseph Burnett exercised stock options to acquire 20,942 shares of Common Stock at $3.24 per share. He paid the exercise price in cash and no shares were sold; all shares received were retained.
Following the exercise, Burnett directly owns 116,842 shares of Common Stock. In addition, 193,231 shares are held indirectly through the Joseph M. Burnett Trust dated 10/20/2022, where he serves as trustee.
ClearPoint Neuro, Inc. provides an overview of its business and risks as a commercial-stage medical device company focused on minimally invasive neurosurgical procedures and biologics/drug delivery. It reports an aggregate market value of about $328 million for non-affiliate common stock as of June 30, 2025, and 29,663,875 shares outstanding as of March 6, 2026.
The company highlights two integrated components: neurosurgical devices, including the ClearPoint navigation platform, ClearPoint Prism Neuro Laser Therapy System, SmartFrame OR, and the newly added IRRAflow Active Fluid Exchange System from its 2025 IRRAS acquisition; and a growing biologics and drug delivery services business with more than 60 partners. It emphasizes multiple FDA clearances and a De Novo marketing authorization for the SmartFlow Neuro cannula in AADC deficiency, while summarizing extensive risk factors around integration of IRRAS, customer concentration, regulatory approvals, reimbursement, debt, and ongoing losses.
ClearPoint Neuro reported strong top-line growth for 2025 while remaining loss-making and investing heavily for future expansion. Total revenue rose to $37.0 million from $31.4 million, an 18% increase, with fourth-quarter revenue up to $10.4 million from $7.8 million, or 34% growth.
Biologics and drug delivery revenue grew 10% to $19.0 million, and neurosurgery navigation and therapy revenue rose 44% to $14.8 million, while capital equipment and software declined 18% to $3.1 million. Gross margin held at 61%, but operating expenses increased 21% to $46.9 million, driving a wider net loss of $25.5 million versus $18.9 million.
The company completed the IRRAS Holdings acquisition, added access to an extra $20.0 million under its Oberland Capital note facility, and ended 2025 with $45.9 million in cash and cash equivalents, up from $20.1 million. For 2026, ClearPoint Neuro projects revenue between $52.0 million and $56.0 million.
ClearPoint Neuro Chief Financial Officer Danilo D'Alessandro settled 32,627 restricted stock units into an equal number of shares of common stock on their scheduled vesting date.
Of these, 16,601 shares were delivered back to ClearPoint Neuro at $11.53 per share to cover tax withholding, leaving him with 102,684 shares of common stock held directly.
ClearPoint Neuro, Inc. CEO and President Joseph Burnett settled 84,829 restricted stock units, receiving the same number of common shares upon vesting. To cover tax withholding obligations, 43,161 common shares were delivered back to ClearPoint Neuro at $11.53 per share, which is not an open-market sale. Following these transactions, Burnett holds 95,900 common shares directly and an additional 193,231 common shares indirectly through the Joseph M. Burnett Trust dated 10/20/2022, where he serves as trustee.
ClearPoint Neuro, Inc. Chief Business Officer L. Jeremy Stigall settled restricted stock units into common shares as part of scheduled vesting. Each unit converts into one share of common stock, and this transaction reflects the routine exercise or conversion of 30,995 restricted stock units.
In connection with the vesting, 15,151 shares of common stock were delivered back to ClearPoint Neuro at $11.53 per share to satisfy tax withholding obligations, rather than being sold in the open market. After these transactions, Stigall directly holds 108,482 shares of common stock.
ClearPoint Neuro, Inc. Chief Operating Officer Sabra Mazin exercised and settled 26,101 restricted stock units into the same number of shares of common stock on their scheduled vesting date. Each unit represented a right to receive one share of common stock.
To cover tax withholding obligations tied to this vesting, 13,281 common shares were delivered back to ClearPoint Neuro at 11.5300 per share, a non-market, tax-withholding disposition rather than an open-market sale. After these transactions, Mazin directly holds 67,343 shares of common stock.
ClearPoint Neuro, Inc. Schedule 13G shows that MAK Capital Fund LP, MAK Capital One L.L.C. and Michael A. Kaufman beneficially own 1,729,611 shares of Common Stock, representing 6.1% of the class as of 03/13/2026. The filing reports shared voting and dispositive power over those shares. The excerpt cites 28,423,308 shares outstanding as of October 27, 2025 per the issuer's Form 10-Q.